Subtype
Pancreatic Carcinoma
CI-CAN-00003562Explore in graph →
488 active trials5 approved drugs31 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003562Explore in graph →
Clinical trials
1,381 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03384238 | Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery | recruiting | Phase 1 / Phase 2 | 27 | George PoultsidesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07477418 |
| PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)(PRISM-TAMP) |
| not yet recruiting |
| Phase 1 / Phase 2 |
| 10 |
| University of VermontOTHER |
| 1 |
| Mar 17, 2026 |
| clinicaltrials |
| NCT06646055 | AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 110 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07441174 | IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 92 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05642962 | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) | active not recruiting | Phase 1 / Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07145255 | Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | MBrace TherapeuticsINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06384560 | Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)(PREOPANC-5) | recruiting | Phase 1 / Phase 2 | 66 | Amsterdam UMC, location VUmcOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT02336087 | Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery | active not recruiting | Phase 1 | 21 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07030283 | Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis | recruiting | Phase 1 | 10 | University of Colorado, DenverOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04150042 | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells(SHARON) | recruiting | Phase 1 | 24 | General Oncology, Inc.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07348107 | ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.(ATARI-PDAC) | not yet recruiting | Phase 1 | 10 | Daniel BreadnerOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05156866 | First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer | active not recruiting | Phase 1 | 163 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Jan 13, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06693986 | Adenovirus (RGDCRAdCOX2F) | recruiting | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04146298 | Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 30 | Changhai HospitalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06730009 | Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients | recruiting | Phase 1 / Phase 2 | 42 | Medigen Biotechnology CorporationINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07284277 | TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) | recruiting | Phase 1 / Phase 2 | 30 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT07259590 | A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation | recruiting | Phase 1 / Phase 2 | 126 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06396091 | A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer | active not recruiting | Phase 1 | 12 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT04821284 | Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 120 | Flemming ForsbergOTHER | 2 | Nov 4, 2025 | clinicaltrials |
| NCT03484299 | Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma | recruiting | Phase 1 | 20 | University of LouisvilleOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04888312 | Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients(OPTIMIZE-1) | active not recruiting | Phase 1 / Phase 2 | 94 | Alligator Bioscience ABINDUSTRY | 3 | Oct 8, 2025 | clinicaltrials |
| NCT03245541 | Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07179692 | CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors | recruiting | Phase 1 | 108 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04361708 | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies(I-FLOAT) | recruiting | Phase 1 | 54 | University of ChicagoOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06182072 | ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 1 | 46 | ProDa BioTech, LLCINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07198321 | A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 450 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05116072 | Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula(TPIAT-01) | recruiting | Phase 1 / Phase 2 | 36 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05209074 | Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 16 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05669482 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer(RAMP205) | active not recruiting | Phase 1 / Phase 2 | 40 | Verastem, Inc.INDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | recruiting | Phase 1 | 292 | Bicara TherapeuticsINDUSTRY | 3 | Aug 15, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07066995 | Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer(BAH2573-102) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05607953 | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 60 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06596915 | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 167 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 17, 2026source: clinicaltrials